07:00 , Sep 5, 2016 |  BC Week In Review  |  Financial News

Egalet completes private placement of senior notes

Egalet Corp. (NASDAQ:EGLT), Wayne, Pa.   Business: Drug delivery, Neurology, Cardiovascular   Date completed: 2016-09-01   Type: Private placement of senior notes   Raised: $40 million   Placement agent: Morgan Stanley   Investor: Institutional investors...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Daiichi Sankyo, Egalet deal

Egalet purchased Sprix ketorolac tromethamine nasal spray from Daiichi Sankyo’s Luitpold Pharmaceuticals Inc. subsidiary for $7 million. The intranasal ketorolac analgesic is approved in the U.S. to treat adult patients with moderately severe pain for...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Sprix ketorolac tromethamine update

Daiichi's Luitpold Pharmaceuticals Inc. company said a group of academic researchers began the AMPED registry to evaluate Sprix nasal spray with or without oral narcotics, or oral narcotics alone in patients seeking emergency medical care...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Luitpold Pharmaceuticals Inc., Daiichi Sankyo sales and marketing update

Luitpold's Regency Therapeutics division and Daiichi Sankyo launched Sprix ketorolac tromethamine nasal spray in the U.S. to manage moderate to severe pain. The analgesic was approved by FDA last May. The wholesale acquisition price is...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

Sprix regulatory update

FDA approved an NDA from Roxro for Sprix ketorolac tromethamine nasal spray for short-term management of acute moderate to severe pain. Roxro said it is in negotiations for a commercialization partner for the analgesic. Roxro...
00:17 , May 18, 2010 |  BC Extra  |  Company News

FDA approves Roxro's Sprix

FDA approved an NDA from Roxro Pharma Inc. (Menlo Park, Calif.) for Sprix ketorolac tromethamine nasal spray for short-term management of acute moderate to severe pain. Roxro said it is in negotiations for a commercialization...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

Acuvail 0 regulatory update

Allergan said FDA approved an NDA for Acuvail ketorolac tromethamine ophthalmic solution to treat pain and inflammation following cataract surgery. Allergan expects to launch the ophthalmic formulation of 0.45% ketorolac, a non-steroidal anti-inflammatory drug (NSAID),...
08:00 , Dec 6, 1993 |  BC Week In Review  |  Company News

TheraTech deal

THRT received an undisclosed milestone payment from Syntex Inc., its development partner for Toradol (ketorolac tromethamine) analgesic transdermal patch. THRT said the milestone was reached when target blood levels were achieved using the patch. TheraTech...